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Dr Laragh: Why don't we go around the table and let everyone say some things about the work they are doing and the particular aspects of hypertension they are interested in at this time. We have a very wide ranging group of hypertension experts assembled here tonight, and I think that everyone will be excited to learn what areas are of interest to each of our participants. Why don't we start with Jean Sealey?
Jean E Sealey, DSc, is Research Professor Emeritus of Medicine in Physiology & Biophysics, Weill Medical College of Cornell University.
Dr Sealey: My primary professional interest is to explain to medical practitioners how and why the plasma renin test is an invaluable tool for the diagnosis and treatment of their hypertensive patients-because it discriminates the patient whose hypertension is caused by excessive volume expansion (renin suppressed) from one whose hypertension is caused by excess renin (renin not suppressed).
In an untreated hypertensive patient, a suppressed plasma renin test reveals that this patient's hypertension is caused by excessive sodium retention and volume expansion (PRA less than 0.65 ng/ml/h; Direct Renin less than 5 mU/ml). We call this a 'V' patient. In contrast a plasma renin test that is not suppressed (PRA greater than 0.65 ng/ml/h; Direct Renin greater than 5 mU/ml) reveals that the hypertension is caused by too much renin for the level of blood pressure. We call this an 'R' patient. The renin test identifies V and R patients each of whom responds differently to V or R antihypertensive drugs. The blood pressure of V patients responds best to V drugs-diuretics, aldosterone receptor antagonists and calcium channel blockers. The blood pressure of R patients responds best to antirenin system R drugs-ACE inhibitors, angiotensin receptor blockers and b-blockers. Moreover, a primary R drug is only a placebo in a V patient while a primary V drug in an R patient raises plasma renin levels even higher and may even worsen the hypertension.
However, more than that, the renin test leads to a logical approach for the treatment of patients already taking antihypertensive drugs who are seemingly unresponsive. There are only two reasons for resistance to antihypertensive drugs: (i) excessive volume expansion: that patient's plasma renin is suppressed-patient needs more volume depletion and doesn't need R drugs. (ii) Excessive salt depletion: renin very high (46.5 ng/ml/h)-this patient's lively renin secretion has over-reacted to diuretics, raising renin even higher and in so doing preventing blood pressure from falling. Such patients need to cut back on the diuretics and use only R drugs instead.
By understanding of how the renin system works, and by measuring plasma renin levels, deciding on the best antihypertensive treatment strategy is as easy as falling off a log! Dr Laragh: This is certainly an apropos summary of the work Jean and I, and many others, have been engaged in for the last 50 years. We have published over 900 articles on the topic of renin and hypertension and believe that this approach is mechanistically correct. The holy grail would be to control the majority of individuals with elevated blood pressure with one drug, based on whether they are a V or an R patient.
Well, let's move on around the Dr Houston: A highly significant inverse relationship exists between the decline in age-adjusted cardiovascular disease mortality in the US based on the National Vital Statistics Registry and the concurrent rise in ESRD based on the USRDS annual data reports from 1980 to 1998. Annual increases in diuretic expenditure and distribution are associated with increases in ESRD incidence rate growth 2 years later. Decreases in diuretic distribution are associated with reductions in ESRD incidence growth 2 years later. The predominant diuretics used were HCTZ and furosemide.
A statistically significant (P ¼ 0.03) direct linear association between changes in diuretic distribution and subsequent changes in the growth rate of ESRD exists. The beneficial effects of diuretics related to CHF, CVA and, to a lesser extent, CHD may simultaneously be either permissive of nephrotoxicity or directly nephrotoxic.
Published hypertension trials and surveys, such as EWPHE, HEP, STOP, NHANES III survey, Syst-EUR, SHEP, INSIGHT and ALLHAT, have independently demonstrated this. Possible mechanisms for renal injury with chronic diuretic therapy include glomerulosclerosis with glomerular capillary hypertension, mesangial matrix expansion, mesangial hypercellularity, dyslipidaemia, hyperglycaemia, hyperuricaemia and increased intrarenal oxidative stress.
Diuretic therapy stimulates growth-promoting, profibrotic or proinflammatory mediators such as homocysteine, PAI-1, PDGF, LDL-cholesterol, aldosterone, endothelin and angiotensin II levels, TGF-b, TNF-a and COX-2.
Calcium channel blockers (CCBs), ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown renal protective effects and slowing of the development of glomerulosclerosis while achieving the same magnitude of blood pressure reduction seen with HCTZ therapy.
NHANES III survey noted an increased prevalence of elevated creatinine in patients receiving diuretics for hypertension compared to those receiving any other antihypertensive medication category.
In addition, exposure to thiazide diuretics has been epidemiologically linked to an increased risk for the development of renal cell carcinoma, and in patients with congestive heart failure, the mortality is higher in those receiving chronic diuretic therapy than in patients not receiving long-term diuretic therapy. Since diuretic acquisition cost is relatively inexpensive, superficial analysis might suggest that diuretic therapy is more 'cost-effective' than alternative therapies. However, the economy of low acquisition cost is negated by concomitant expenses of treating the iatrogenic chronic complications (new onset diabetes, dyslipidaemia, gout, hypokalaemia, renal carcinoma, ESRD).
Dr Laragh: Thank you, Mark. This is very important work indeed, and we need to get the word out to practitioners who, under the influence of government-sponsored guidelines, are still in the 'diuretics first' camp. Dr Gavras: I have given a lot of thought recently to the future of hypertension research. The last 30 years have seen some tremendous advances in this multifactoral disease. The successes in the drug therapy of hypertension have turned out to be a bonanza for the prevention and treatment of myocardial infarction and congestive heart failure. The future challenges include improving our diagnostic evaluation. One new goal is to develop telemetric evaluation of hypertension. My enthusiasm comes from research we are doing in our lab with rats. We can measure blood pressure by telemetry within 1 mmHg in our rats. We don't have this for humans. Since we know that as little as 3 mmHg in blood pressure can make a difference in 15-20% of morbidity and mortality, developing technology that can actually see how blood pressure behaves and accurately determine blood pressure levels for weeks or months is very important.
Oxidative stress needs a marker for clinical diagnostic testing. We do not have a single marker for clinical diagnostic test that we can apply to assess patients for oxidative stress. Pregnancyinduced hypertension has had little attention in recent decades. Diagnostic markers for risk for toxemia are needed. Childhood hypertension needs more attention. The NIH has spearheaded the development of some wonderful new initiatives in the treatment of childhood hypertension. Endothelial dysfunction is an interesting concept that needs better chemical diagnostic markers. Plethysmographic evaluation gives limited information, it is cumbersome, and people question the specificity of this particular test. We need to see if interventions to correct endothelial dysfunction are useful in preventing hypertension because it is not clear whether endothelial dysfunction is the cause of hypertension or is a consequence of it. Assessing microcirculation, in the heart, in the brain, in the kidney, is an area that needs new research to develop imaging or other methods to evaluate these resistance vessels. Current methods are cumbersome and inaccurate. We cannot actually see what is going on in the arterioles and not a lot of work is being carried out in this area other than myocardial perfusion imaging.
It helps to predict hypertension if we understand the genomics. A lot of work has been performed with some early enthusiasm, but these things take time. With regard to the diagnosis of monogenic disorders, we have four or five genes that increase blood pressure-prototypes to see how these genotypes misbehave in some rare families-but these results have not yet shed light on the causes of essential hypertension, which results from interaction of genes with environment. We should continue wisely. We are relying on the expression analysis, microarray technology and serial analysis of gene expression (SAGE), to discover how genes get activated to cause hypertensive damage. We need to develop new technologies. I say to the next generation, don't stay with the old methods; find new ones. For example, could gene treatment of the renin-angiotensin system cure some patients with hypertension? And I'm not talking about treating hypertension but curing it. I throw this out as an idea; it doesn't mean it is going to work that way.
Hypertension and target organ damage is an area that needs more attention as we focus on treatment of this lifelong disease. We need to better define the links between hypertension and insulin resistance, between hypertension and obesity, links between hypertension and hyperuricaemia, reversal of arterial stiffness. These are all very important areas.
All of this is nice, but we need population studies-epidemiologic studies that translate new information into clinical practice by validating our research with outcomes data. ASH and its chapters have a foundation for addressing this need. Researchers like Brent Egan are addressing this quite well.
Dr Laragh: And we will hear from Dr Egan before too long. Thank you, Harry, for you insights. As my fellow New Yorker, Yogi Berra, would say, 'It's tough to make predictions, especially about the future'. Dr Johnson: Our research has focused on studies of the pathogenesis of essential hypertension. We have been particularly interested in the role of uric acid. Interestingly, it has been known since the original reports on hypertension that gout is associated with hypertension, and studies by Drs Cannon and Laragh in the 1960s showed a strong relationship between uric acid, hypertension and renal disease. Furthermore, there are now at least six epidemiological studies that have found that an elevated uric acid independently predicts the development of hypertension. However, most authorities have continued to believe that uric acid is likely a marker of cardiovascular risk since it is often elevated in the subject with established risk factors such as renal disease, obesity, insulin resistance or dyslipidaemia. An important point, however, is that until recently no one had determined the effect of raising uric acid on blood pressure in animals. To do this, we raised uric acid in rats by blocking uricase, which is an enzyme that degrades uric acid to allantoin, and which is present in most mammals but is absent in humans due to a mutation that occurred over 10 million years ago. Amazingly, rats made hyperuricaemic developed hypertension. We then showed that the hypertension was mediated by a uric acidinduced endothelial dysfunction as well as a stimulation of the renin-angiotensin system. This initial phase of hypertension was salt-resistant and would correspond to the 'R' type of hypertension described by Drs Sealey and Laragh. Over time, however, we found that uric acid induced microvascular disease in the kidney leading to the development of arteriolosclerosis. Once the microvascular disease developed, the hypertension was then driven by the kidney, the serum uric acid was no longer critical, and the hypertension became volume dependent.
These studies suggested uric acid may be most important in the initiation of hypertension. To examine this possibility, Dan Feig and I looked at new onset hypertension in an adolescent clinic, and found that nearly 90% of new onset hypertension is associated with uric acid levels 45.5 mg/dl vs 0% in 63 controls; we are now doing a NIH-funded placebo-control trial to determine if lowering uric acid in these subjects results in lower blood pressure.
One of the implications of our work relates to diuretics, since they raise serum uric acid in addition to facilitating sodium excretion. It has been known for many years that diuretics may not provide as much cardiac protection as they are predicted for the degree of blood pressure lowering. One possibility is that the hyperuricaemia induced by diuretics may counter some of its benefits. We currently have submitted a proposal to study this in the African American with Stage I hypertension, by determining if lowering uric acid concomitant with diuretics may provide better BP control, with improvement in endothelial function and a reduction in the plasma renin activity.
Dr Laragh: To the extent that your work can show evidence of uric acid being responsible for inducing endothelial dysfunction, stimulation of the reninangiotensin system, microvascular disease in the kidney, and arteriolosclerosis, we can begin to see why our traditional treatment of this metabolic disease of hypertension hasn't protected that most metabolic organ-the kidney. The last few decades have witnessed hypertension control rates improving from 10 to 34%. During this same time stroke incidence has fallen-stroke is more of a pressure phenomenon-but ESRD rates have doubled. You are providing us with some very valuable knowledge, Rick, and we need to confirm the evidence with clinical trials, but these are great insights.
Next Dr Blumenfeld: We are doing some work with autosomal dominant polycystic kidney disease. This is the most common inherited kidney disease, affecting more than 400 000 people in the US and 5 million people worldwide. It is the 4th most common cause of kidney failure requiring dialysis and/or kidney transplantation. Most polycystic kidney disease patients develop kidney failure by 60 years of age, that varies widely, even among family members. High blood pressure and large kidney size have been linked with the development of kidney failure in polycystic kidney disease.
The genes involved are referred to as PKD1 and PKD2. The reason for doing the research that we are doing is that we hope to learn about the mechanisms that elevate the blood pressure and cause the kidney function to worsen in polycystic kidney disease patients. Specifically, we will be measuring the levels of hormones in the blood and urine that normally regulate blood pressure and will determine if these hormone levels are higher in PKD1 than PKD2 patients. I can't talk about results because we are not at that stage yet.
We are doing a complete work-up at Inpatient Studies at the Rockefeller University Hospital. It includes a 24-h urine collection, a history and physical examination, a captopril test, magnetic resonance imaging (MRI), an echocardiogram, and genetic testing. We are still signing people up for the study.
Another area that really interests me is primary aldosteronism. This is a lot more common than most practitioners realize. We ought to be screening for it more and dealing with it primarily. Of 50 or so patients with primary aldosteronism who had adrenalectomy, those most likely to be cured were younger and had lower plasma renin activity. In patients with adenomas who were cured or improved, aldosterone secretion was more likely to lateralize. A lot more vein sampling is being carried out now. Tests that distinguished adenomas from adrenal hyperplasia included the postural stimulation test, urinary excretion rates of 18-oxocortisol and 18-hydroxycortisol, and adrenal vein sampling. Hypertension specialists are doing a good job making this distinction. Primary aldosteronism represents the most common form of secondary hypertension, so we are trying to get more generalist physicians to recognize those patients who need scrutiny for this condition. Dr Brown: My studies developed from an interest in using variation in drug response in hypertension as a clue to underlying genetic variation in hypertension. We therefore planned to rotate patients among each of the main classes of antihypertensive drugs, in a random, crossover fashion. Some of the studies were open-label in design, but some were completely double-blind and placebo-controlled. Always we repeated each patient's best drug at the end of rotation, sometimes with 24-h ABPM in addition, in order to distinguish systematic from random variation in blood pressure response.
Thinking that the relationship between pathogenesis and response may be clearest early in hypertension, and because (at least in the UK) young patients are the easiest to recruit prior to any exposure to drug treatment, our first rotation study restricted recruitment to patients under the age of 50 years. In all, 56 young Caucasians took part. As we should perhaps have predicted from John Laragh's work, the mean blood pressure response to both ACE inhibitors and b-blockers was almost twice as great as that to calcium blockade or diuretics. The crossover design allowed us to show that there was a high degree of correlation between response to ACE inhibition and b blockade, and between calcium blockade and diuretic therapy-but not between the other four possible pairings. In other words, there was only two main patterns of response-what John, of course, would call V and R. During preparation of the manuscript, I was struck by the wonderful piece of serendipity according to which the initials of the four major drug classes are the first four letters of the alphabet; and moreover, the two pairs of correlations are between the members of the 'AB' and 'CD' categories. This allowed us to propose a mnemonic AB/CD rule for the treatment of hypertension that John will recognize as little more than a restatement of his long-held and long-studied ideas. The rule predicted that in the older patients taking part in recent outcome trials there would on average be a greater blood pressure response to diuretic or calcium blocker than to an ACE inhibitor (as in ALLHAT) or ARB (as in VALUE). However, age and ethnic group are the very poor man's surrogate for measurement of plasma renin; advent of the cheap, automated assays for renin mass should now rationalise and revolutionise individual management of hypertension.
Dr Laragh: Thank you, Morris. Next I would like us to meet Dr John Standridge. Dr Standridge is a family physician who still delivers babies and makes house calls, but is also a Specialist in Clinical Hypertension, directs geriatric training at a family practice residency, and works in the field of addiction medicine as well. John wrote an article that took ALLHAT to task and we published it last month in the American Journal of Hypertension. John, you sound busy. We are glad you could join us tonight.
John B Standridge, MD, FAAFP is Associate Professor of Family Medicine, University of Tennessee Health Science Center College of Medicine, Chattanooga Unit.
Dr Standridge: Just as an artist needs an audience, the rest of you here tonight need me. I represent the physicians out there who actually read, understand, and apply current research findings to clinical practice. Listening to Drs Houston and Johnson describe their research concerning the potential nephrotoxicity associated with diuretic-influenced hyperuricaemia is interesting and disconcerting. It adds one more facet to the reservations I have expressed regarding ALLHAT. The ALLHAT conclusion that thiazide diuretics should be preferred for first-step antihypertensive therapy is unjustified because, unlike ANBP2, ALLHAT was not a trial that initiated therapy for hypertension. ALLHAT was primarily a study that compared irrational drug combinations chosen without regard to an individual's renin status. The lisinopril limb was denied a volume drug in a patient population at risk for heart failure and when predictably worse outcomes developed, the authors said, 'See? Diuretics are superior'. Not only was the heart failure subset analysis not prospectively established, it would not be ethical to design such a study.
The thing that upset me the most about ALLHAT was its mindless endorsement in the ADA journal Clinical Diabetes. ALLHAT was neither designed nor of sufficient length to detect the poorer outcomes that are inevitable with the increased rates of diabetes detected in the chlorthalidone limb. Additionally, SHEP and other studies confirm the diuretic-diabetes link. An article published this month in Hypertension shows a tripling of relative risk for first cardiovascular event in hypertensive patients who develop diabetes. ALLHAT was not designed to make the conclusions claimed by its authors and blindly adopted by JNC-7.
As family physicians, if we do not take the time and trouble to understand the mechanisms underlying the diseases that we commonly treat, we are still just shaking rattles and practicing voo-doo. Then when imperfect guidelines come out, based on flimsy science, we buy into it like everyone else. It would help if there were enough solid evidence to inform our treatment decisions on even half of the human conditions that we encounter, but there isn't. Truly evidence-based medicine will have to wait for much of what we do.
Dr Laragh: Thank you, John. It is good to know that practicing physicians and family doctors are so involved in the hypertension field. We are trying to encourage more generalist physicians to become certified as specialists in hypertension.
Another group that is working on developing the specialists programme is the American Society of Hypertension Chapter representing the Carolinas and Georgia where Brent Egan was recently president. Brent has been doing some very important work at the community and state levels. What can you tell us about that, Brent? Brent M Egan, MD, Professor of Medicine and Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
Dr Egan: The Hypertension Initiative has as its founding goal to help change South Carolina from a leader in cardiovascular disease to a model of cardiovascular health. The intent is to reduce cardiovascular disease and end-stage renal disease by improving blood pressure control rates among South Carolinians from 25 to 50% over the next 5 years. We are focusing on primary care physicians as the key to success. We have developed a good working relationship with a large cadre of primary care providers through the Experts in Hypertension Seminar Series, which began in April, 1999. Physicians that have a special interest in and commitment to hypertension are encouraged to become Clinical Hypertension Specialists through the American Society of Hypertension certifying examination. Currently, there are 34 Clinical Hypertension Specialists in South Carolina with a goal of 110 (5% of primary care providers) by 2009 with at least one Hypertension Specialist in each of the State's 46 counties. These specialists will provide education on hypertension to their medical colleagues, treat resistant hypertension, and help us track hypertension, diabetes, and cholesterol control rates through the Hypertension Initiative's data monitoring and feedback programme. In addition to facilitating the development of a statewide network of Hypertension Specialists, the Initiative is working with over 400 providers to track the treatment and control of hypertension, lipid disorders, and diabetes in their patients. The database, updated quarterly, has grown to include more than 80 000 hypertensive patients. The database provides one objective measure for the success of this statewide initiative in improving cardiovascular risk factor control.
Of note, the Initiative received two awards this year from the US Department of Health and Human Services. The first award recognized the Initiative as a National Best Practice Model. The second award, presented by Secretary Tommy Thompson during the celebration for the 40th Anniversary of the Civil Rights Amendment, recognized the Initiative for its effort in reducing health disparities. Given the widespread interest, the Hypertension Initiative has crossed the South Carolina borders to work collaboratively with other groups with a commitment to the treatment and control of hypertension and concomitant risk factors.
Personally, my interests involve the obesity epidemic that is driving metabolic syndrome-related health problems and tripling coronary heart disease risk. Sympathetic hyperfunction in the pathogenesis and complications of the metabolic syndrome produces higher blood pressure, a more active renin-angiotensin system, additional insulin resistance, faster heart rates, and excess cardiovascular disease and sudden death. While there are several factors that may participate in the metabolic syndrome and sympathetic hyperactivity, our work focuses mainly on the role of nonesterified fatty acids. High plasma nonesterified fatty acids are especially interesting as a risk factor for hypertension and sudden death. In human studies, nonesterified fatty acids raise blood pressure, heart rate, and a 1 -adrenoceptor vasoreactivity, while reducing baroreflex sensitivity, endothelium-dependent vasodilatation, and vascular compliance. We are working to further identify the mechanisms and consequences of sympathetic dysfunction in the metabolic syndrome to help provide insights to improve cardiovascular risk and outcomes.
Dr Laragh: Thank you, Brent. I know we all appreciate your good work and your efforts to get more doctors certified as Specialists in Clinical Hypertension.
Dr Jay Meltzer is a long-time friend and colleague, and professor emeritus at Columbia-Presbyterian University. There is no predicting what Dr Meltzer will share with us but we can be certain it will be instructive. Jay, what would you like to discuss? Jay I Meltzer, MD, is Clinical Professor of Medicine at College of Physicians and Surgeons, Columbia University, New York, NY.
Dr Meltzer: I would like to discuss why I use an intermittent dosing schedule for diuretic treatment of patients with essential hypertension. Before oral diuretics, the drug of choice for the treatment of congestive heart failure was parenteral mercuhydrin. It was given in a single morning dose, and then observed over a period of days for its diuretic and natriuretic effect on total body weight and specific manifestations of fluid retention. When oral diuretics were developed, a similar protocol was used. A single large oral dose of a thiazide was given and the degree of diuresis noted. If more diuretic was needed more would be given, but not till the initial effect had leveled off. This enabled the clinician to measure how well the diuretic was working and give only what was necessary, minimizing side effects.
When thiazide diuretics were first used to treat hypertension, the heart failure model was not adapted and they were given daily. This surprised me but I realized that the doses used were high because those investigators tested the initial treatments on severe hypertension and were anxious to obtain measurable effects rapidly. Under those conditions, Pickering noted in 1966 that the doseresponse curve for all thiazides was relatively flat. However, no one ever gave less than the equivalent of 25 mg of hydrochlorothiazide daily. No one ever admitted that one couldn't really say it was flat without going lower. Some note was taken of the relation of the diuretic dose to the daily salt intake but no one really studied that relationship carefully because it was generally accepted that patients preferred taking a diuretic to going on a low salt diet. No one compared the heart failure model with the new daily dosage to see which produced the greatest gain/risk benefit.
My hypertension therapeutics was always directed toward the achievement of clearly defined, calibrated home blood pressure goals, monitored by well-taught patients, usually to a level of 135 systolic or less. Focused on blood pressure goals, I was not committed to any specific drug protocol. This freed me to continue to use the heart failure model of diuretic therapy as long as goals were well met.
I sought the middle of the dose-response curve with all medication. This area of the curve defined the maximum difference between the desired effect and all the unwanted effects. I also sought a response to the lowest dose possible. So the habit of dosing diuretics intermittently served me well, enabling me to test the response to doses below 25 mg daily.
The mechanism of the blood pressure response to thiazide diuretic was understood by the early 1960s. The natriuetic response was more or less complete by 2-4 days on the daily dose and further treatment did not change salt balance or extracellular fluid volume. In fact, the initial decrease in cardiac output, plasma volume, and extracellular fluid volume reconstituted over a period of weeks to months. The peripheral resistance initially fell as cardiac output lowered renal plasma blow. How it came back down has never really been explained, but in any case the blood pressure lowering effect was maintained during all those changes. The postdiuretic physiology at 3-4 months and 1 week is totally different.
I prescribed diuretics every other day (three times per week, Monday, Wednesday, Friday was easier to remember), and could achieve goal blood pressures similar to those claimed for daily use. It was rare that I needed to go to daily diuretics to obtain a better effect, though I never hesitated doing so if necessary. I have continued to use this schedule to this day, 45 years after I began. I always believed it was the fall in pressure that produced the therapeutic effect, not the manner of dosing. Some of my blood pressure success with low-dose diuretics may have been due to efforts made to get patients to avoid a high salt diet and keep their sodium intake between 80 and 100 mmol/day or less.
Sir George Pickering noted the three principle side effects of diuretics in his 1966 book 'High Blood Pressure', potassium depletion, diabetes and gout. He always assumed thiazide-treated patients were potassium depleted and demanded potassium-sparing agents when giving diuretics fearing hypokalaemia as vasculotoxic. My hope was that intermittent dosing would reduce the incidence of potassium depletion and the other metabolic effects by allowing the body to recover on the off days. While I never measured the net salt balance (that required a metabolic balance ward) it is probable that alternate dosage eventually went through the same physiologic changes as daily doses in most patients after 3-4 months. The newest trials use doses of chlorthalidone of 12.5 mg daily, which can't be too different from 25 every other day, but this remains to be tested but probably never will be. It would be valuable to know whether the many known side effects of thiazides, in addition to hypokalaemia, diabetes and gout, such as hyperlipidaemia, hypomagnesaemia, hyperuricaemia, ventricular ectopy, and sudden death, postural hypotension in the elderly and erectile dysfunction could be reduced by intermittent therapy. Dr Shimosawa: In order treat metabolic syndrome effectively, current therapeutic agents seem not sufficient. Blood pressure, hyperlipidaemia, obesity and diabetes are treated separately and the patients are required to take many pills and drug compliance is not always high enough. In order to find a new effective therapeutic target, from the point of view of organ protection, our research has focused on oxidative stress. Renin-angiotensin-aldosterone axis is an important factor in producing oxidative stress as well as high glucose, ageing and adipocytokines. We recently established adrenomedullin knockout mice. Adrenomedullin was first discovered as a vasodilatory peptide from the pheochromocytoma cell. However, it is now recognized as a ubiquitous circulatory peptide and it possesses pleiotropic effects. Among its physiological effects, we clarified its antioxidative effect by using knockout mice. Our animal model showed higher oxidative stress together with marked vascular damage and insulin resistance by angiotensin II loading or natural ageing. Also adrenomedullin effectively suppressed reactive oxygen species production in vivo and reversed organ damages in animal model. Recent study of our group showed adrenomedullin can antagonize angiotensin II signalling. Adrenomedullin peptide is still far away from clinical usage, but so far, inhibition of renin-angiotensin system with this peptide appears to be clinically relevant to protect organs in metabolic syndrome patients.
Also, we are interested in establishing a total renin assay system that will be applicable in clinical usage to differentiate salt-sensitive patients from nonsalt sensitive patients, and to apply tailor-made medication design to each patient. I would like to discuss this in detail with Dr Sealey later.
Dr Laragh: Also from Tokyo is Dr Toshiro Fujita, who has been researching salt sensitivity and insulin resistance for decades. Dr Fujita, your insights are always most welcome.
Toshiro Fujita, MD, PhD, Professor and Chairman, Department of Internal Medicine, Faculty of Medicine, the University of Tokyo, Tokyo, Japan, and President, Japanese Society of Hypertension.
Dr Fujita: A quarter of a century ago, I and Bartter at NIH reported that, according to blood-pressureresponse to salt loading, patients with essential hypertension could be divided into two groups; salt-and nonsalt-sensitive hypertensive ones. Chronic salt loading increases blood pressure in salt-sensitive patients, but potassium supplementation could inhibit salt-induced elevation of blood pressure. Recently, we found salt loading induced insulin resistance in Dahl salt-sensitive (S) rats, through overproduction of oxidative stress, but not in Dahl salt-resistant rats. Moreover, potassium supplementation could normalize salt-induced impairment of insulin sensitivity in Dahl S rats, through the inhibition of oxidative stress production. Thus, high salt diet induces not only hypertension but also insulin resistance in saltsensitive animals and man, resulting in the progression of atherosclerosis. In contrast, diets rich in potassium could not only decrease salt-induced BP rise but also improve insulin resistance, resulting in the inhibition of cardiovascular events. Accordingly, JNC-7 guideline recommends fruits and vegetables as one of lifestyle modifications for the treatment of hypertension, since the DASH study confirmed the antihypertertensive effect of potassium. In the SHEP study, the diuretic treatment was effective in reducing stroke incidence in elderly patients with isolated systolic hypertension; this beneficial effect of diuretics was observed in normokalaemic patients, but not in hypokalaemic ones, despite the similar BP reduction. Therefore, I want to dispute the JNC-7 guideline for the recommendation of diuretics only as the first choice drug, although I approve of the JNC-7 guideline for the DASH diet.
Dr Laragh: Thank you, Dr Fujita, and thanks to everyone for a lively and informative evening.
